Mira Pharmaceuticals Inc Dossier - Source-backed chat

Mira Pharmaceuticals Inc

MIRANASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.33

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.72Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $30.4M

Enterprise Value $25.6M

Shares Outstanding 42.1M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company's lead asset, Ketamir-2, is transitioning into a Phase 2a clinical trial for chemotherapy-induced peripheral neuropathy (CIPN), representing a significant clinical milestone in an area with high unmet medical need. Additionally, MIRA recently consolidated its intellectual property by securing worldwide exclusive rights to its pipeline candidates (Ketamir-2, MIRA-55, and SKNY-1), enhancing its strategic flexibility for future licensing or co-development partnerships. However, MIRA remains a pre-revenue company with persistent net losses ($1.15 million in Q1 2026) and a limited cash balance of $4.82 million as of March 31, 2026. Management has explicitly disclosed substantial doubt regarding the company's ability to continue as a going concern, as existing cash is only expected to fund operations into early 2027. Given the high probability of near-term dilutive capital raises and the early-stage nature of its clinical pipeline, a 'Hold' recommendation is warranted until the company secures stable long-term financing or delivers definitive Phase 2a clinical data.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5015%

The bear case is triggered by clinical delays in the Ketamir-2 Phase 2a trial, safety concerns during patient dosing, or an inability to raise capital on favorable terms. Severe equity dilution, a potential reverse stock split to maintain Nasdaq compliance, or failure to secure a strategic partner would severely depress valuation.

Base CaseCentral scenario

$1.2560%

The base case assumes MIRA successfully initiates its Phase 2a trial for Ketamir-2 and continues preclinical development for MIRA-55 and SKNY-1. However, to sustain operations beyond early 2027, the company will likely execute dilutive equity financings or at-the-market (ATM) offerings, keeping the stock price range-bound as the market balances clinical progress against dilution risk.

Bull CaseUpside scenario

$3.1525%

The bull case is driven by positive clinical readouts from the upcoming Ketamir-2 Phase 2a trial in CIPN, which has no currently approved FDA therapies. Successful trial execution, combined with securing a non-dilutive global licensing or co-development partner for Ketamir-2 or MIRA-55 in the second half of 2026, would validate the platform and alleviate going concern risks.

Scenarios reflect our research view at the research date.

Key Investment Merits

Consolidated worldwide exclusive rights for the entire pipeline (Ketamir-2, MIRA-55, and SKNY-1), enhancing strategic flexibility and partnership potential.
Ketamir-2 is advancing to a Phase 2a clinical trial for CIPN, a major market opportunity with no FDA-approved treatments.
U.S. DEA scientific review concluded that Ketamir-2 and MIRA-55 are not considered controlled substances, reducing regulatory and commercialization hurdles.
Successful Phase 1 study of Ketamir-2 in 56 healthy volunteers demonstrated a strong safety profile with no serious adverse events.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern, with cash reserves of $4.82 million only expected to fund operations into Q1 2027.
High likelihood of near-term dilutive capital raises or equity offerings to fund upcoming clinical trials.
Early-stage clinical pipeline with significant development, regulatory, and clinical trial execution risks.
Risk of a potential reverse stock split to maintain compliance with Nasdaq minimum bid price requirements.

Thesis Invalidation Triggers

Failure to initiate or enroll patients in the planned Ketamir-2 Phase 2a clinical trial.
Inability to secure additional financing or strategic partnerships before the end of 2026.
Severe adverse safety signals or lack of efficacy in the Ketamir-2 Phase 2a trial.
Delisting from the Nasdaq Capital Market due to non-compliance with listing standards.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.